Delivery Order SPE2DB20D1100-SPE2DB21FZ87V
- Not listed
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is a delivery order under the company's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical, valued at $999,999,999 through November 2026. The contract covers a comprehensive range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits, to support military...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, provides a range of pharmaceutical products and medical supplies to the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $1,091.76, is a delivery order under an Indefinite Delivery Contract (IDC) with the DLA worth up to $999,999,999.00 through November 2026. The IDC serves as a primary vehicle for Amerisourcebergen to deliver a comprehensive assortment of medications,...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order under the Defense Logistics Agency (DLA) Troop Support Medical Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00. The contract, which runs through November 2026, covers the delivery of a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This includes specialty medications, brand-name and generic...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is a delivery order under the company's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical, valued at up to $999,999,999.00 through December 2025. The contract covers the delivery of a comprehensive range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits,...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is a delivery order under the Defense Logistics Agency (DLA) Troop Support Medical Indefinite Delivery Contract (IDC) valued at $999,999,999. The contract, which runs through November 2026, provides a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally, including specialty medications, brand-name and generic drugs, vaccines, syringes,...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., to deliver a wide range of pharmaceutical products, medical supplies, and equipment. The contract, valued at $1,210.55, is a delivery order under a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which has a potential value of up to $999,999,999.00 and runs through November 2026. This IDC serves as the primary vehicle for...
- This federal contract award is for a delivery order under an Indefinite Delivery Contract (IDC) issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $4,849.37, covers the delivery of a wide range of pharmaceutical products and medical supplies to support military treatment facilities and veterans' healthcare programs. The IDC held by Amerisourcebergen Drug Corp, a subsidiary of Cencora,...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company, to provide pharmaceutical products and medical supplies. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical...
- This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract is a Delivery Order under the DLA Troop Support Medical Indefinite Delivery Contract (IDC) valued at $999,999,999 and running through November 2026. The award is for the provision of a comprehensive range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is an Indefinite Delivery Contract (IDC) valued at $999,999,999 with the Defense Logistics Agency (DLA) Troop Support Medical. The contract, which runs through November 2026, covers a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB21FZ87VDelivery Order
This federal contract award is a delivery order issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract, valued at $97,737.52, is for the supply of pharmaceutical products and medical supplies to support military healthcare programs. The contract is an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of essential medical commodities, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic areas. The contract award does not have a set-aside designation, indicating open competition. In addition to the DLA contract, Amerisourcebergen also holds a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $97.7k | 2/18/21 |